1
|
Rata M, Orton MR, Tunariu N, Curcean A, Hughes J, Scurr E, Blackledge M, d'Arcy J, Jiang Y, Gulani V, Koh DM. Repeatability of quantitative MR fingerprinting for T 1 and T 2 measurements of metastatic bone in prostate cancer patients. Eur Radiol 2025; 35:2487-2498. [PMID: 39505736 PMCID: PMC12021959 DOI: 10.1007/s00330-024-11162-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2024] [Revised: 08/16/2024] [Accepted: 09/28/2024] [Indexed: 11/08/2024]
Abstract
OBJECTIVES MR fingerprinting (MRF) has the potential to quantify treatment response. This study evaluated the repeatability of MRF-derived T1 and T2 relaxation times in bone metastasis, bone, and muscle in patients with metastatic prostate cancer. MATERIALS AND METHODS This prospective single-centre study included same-day repeated MRF acquisitions from 20 patients (August 2019-October 2020). Phantom and human data were acquired on a 1.5-T MR scanner using a research MRF sequence outputting T1 and T2 maps. Regions of interest (ROIs) across three tissue types (bone metastasis, bone, muscle) were drawn on two separate acquisitions. Repeatability of T1 and T2 was assessed using Bland-Altman plots, together with repeatability (r) and intraclass correlation (ICC) coefficients. Mean T1 and T2 were reported per tissue type. RESULTS Twenty patients with metastatic prostate cancer (mean age, 70 years ± 8 (standard deviation)) were evaluated and bone metastasis (n = 44), normal-appearing bone (n = 14), and muscle (n = 20) ROIs were delineated. Relative repeatability of T1 measurements was 6.9% (bone metastasis), 32.6% (bone), 5.8% (muscle) and 21.8%, 32.2%, 16.1% for T2 measurements. The ICC of T1 was 0.97 (bone metastasis), 0.94 (bone), 0.96 (muscle); ICC of T2 was 0.94 (bone metastasis), 0.94 (bone), 0.91 (muscle). T1 values in bone metastasis were higher than in bone (p < 0.001). T2 values showed no difference between bone metastasis and bone (p = 0.5), but could separate active versus treated metastasis (p < 0.001). CONCLUSION MRF allows repeatable T1 and T2 measurements in bone metastasis, bone, and muscle in patients with primary prostate cancer. Such measurements may help quantify the treatment response of bone metastasis. KEY POINTS Question MR fingerprinting has the potential to characterise bone metastasis and its response to treatment. Findings Repeatability of MRF-based T1 measurements in bone metastasis and muscle was better than for T2. Clinical relevance MR fingerprinting allows repeatable T1 and T2 quantitative measurements in bone metastasis, bone, and muscle in patients with primary prostate cancer, which makes it potentially applicable for disease characterisation and assessment of treatment response.
Collapse
Affiliation(s)
- Mihaela Rata
- Department of Radiology, MRI Unit, The Royal Marsden NHS Foundation Trust, London, UK.
- Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK.
| | - Matthew R Orton
- Department of Radiology, MRI Unit, The Royal Marsden NHS Foundation Trust, London, UK
- Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK
| | - Nina Tunariu
- Department of Radiology, MRI Unit, The Royal Marsden NHS Foundation Trust, London, UK
- Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK
| | - Andra Curcean
- Department of Radiology, MRI Unit, The Royal Marsden NHS Foundation Trust, London, UK
| | - Julie Hughes
- Department of Radiology, MRI Unit, The Royal Marsden NHS Foundation Trust, London, UK
| | - Erica Scurr
- Department of Radiology, MRI Unit, The Royal Marsden NHS Foundation Trust, London, UK
| | - Matthew Blackledge
- Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK
| | - James d'Arcy
- Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK
| | - Yun Jiang
- Department of Radiology, University of Michigan, Ann Arbor, Michigan, USA
| | - Vikas Gulani
- Department of Radiology, University of Michigan, Ann Arbor, Michigan, USA
| | - Dow-Mu Koh
- Department of Radiology, MRI Unit, The Royal Marsden NHS Foundation Trust, London, UK
- Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK
| |
Collapse
|
2
|
Trimble C, Sørland K, Wu C, Riel M, Bathen T, Elschot M, Cloos M. Incorporating Spatial and Spectral Saturation Modules Into MR Fingerprinting. NMR IN BIOMEDICINE 2025; 38:e70000. [PMID: 39865307 PMCID: PMC11771585 DOI: 10.1002/nbm.70000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/19/2024] [Revised: 11/11/2024] [Accepted: 01/07/2025] [Indexed: 01/28/2025]
Abstract
In this work, we introduce spatial and chemical saturation options for artefact reduction in magnetic resonance fingerprinting (MRF) and assess their impact on T1 and T2 mapping accuracy. An existing radial MRF pulse sequence was modified to enable spatial and chemical saturation. Phantom experiments were performed to demonstrate flow artefact reduction and evaluate the accuracy of the T1 and T2 maps. As an in vivo demonstration, MRF of the prostate was performed on an asymptomatic volunteer using saturation modules to reduce flow-related artefacts. T1, T2 and B1 + maps obtained with and without saturation modules were compared. Application of spatial saturation in prostate MRF reduced streaking artefacts from the femoral vessels. When saturation is enabled T1 accuracy is preserved, and T2 accuracy remains acceptable up to approximately 100 ms. Chemical and spatial saturation can be incorporated into MRF sequences with limited impact on T1 accuracy. Further sequence optimisation may be needed to accurately estimate long T2 components. Spatial saturation modules have potential in prostate MRF applications as a means to reduce flow-related artefacts.
Collapse
Affiliation(s)
- Christopher G. Trimble
- Department of Circulation and Medical ImagingNorwegian University of Science and TechnologyTrondheimNorway
- Department of Radiology and Nuclear MedicineSt. Olavs Hospital, Trondheim University HospitalTrondheimNorway
| | - Kaia I. Sørland
- Department of Circulation and Medical ImagingNorwegian University of Science and TechnologyTrondheimNorway
| | - Chia‐Yin Wu
- Centre for Advanced ImagingThe University of QueenslandSt LuciaQueenslandAustralia
- ARC Training Centre for Innovation on Biomedical Imaging Technology (CIBIT)The University of QueenslandSt LuciaQueenslandAustralia
- School of Electrical Engineering and Computer ScienceThe University of QueenslandSt LuciaQueenslandAustralia
| | - Max H. C. van Riel
- Computational Imaging Group for MR Diagnostics and Therapy, Department of RadiotherapyUMC UtrechtUtrechtThe Netherlands
| | - Tone F. Bathen
- Department of Circulation and Medical ImagingNorwegian University of Science and TechnologyTrondheimNorway
- Department of Radiology and Nuclear MedicineSt. Olavs Hospital, Trondheim University HospitalTrondheimNorway
| | - Mattijs Elschot
- Department of Circulation and Medical ImagingNorwegian University of Science and TechnologyTrondheimNorway
- Department of Radiology and Nuclear MedicineSt. Olavs Hospital, Trondheim University HospitalTrondheimNorway
| | - Martijn A. Cloos
- Centre for Advanced ImagingThe University of QueenslandSt LuciaQueenslandAustralia
- ARC Training Centre for Innovation on Biomedical Imaging Technology (CIBIT)The University of QueenslandSt LuciaQueenslandAustralia
- Donders Centre for Cognitive Neuroimaging, Donders Institute for Brain, Cognition and Behaviour12 Radboud UniversityNijmegenNetherlands
| |
Collapse
|
3
|
Gaur S, Panda A, Fajardo JE, Hamilton J, Jiang Y, Gulani V. Magnetic Resonance Fingerprinting: A Review of Clinical Applications. Invest Radiol 2023; 58:561-577. [PMID: 37026802 PMCID: PMC10330487 DOI: 10.1097/rli.0000000000000975] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/08/2023]
Abstract
ABSTRACT Magnetic resonance fingerprinting (MRF) is an approach to quantitative magnetic resonance imaging that allows for efficient simultaneous measurements of multiple tissue properties, which are then used to create accurate and reproducible quantitative maps of these properties. As the technique has gained popularity, the extent of preclinical and clinical applications has vastly increased. The goal of this review is to provide an overview of currently investigated preclinical and clinical applications of MRF, as well as future directions. Topics covered include MRF in neuroimaging, neurovascular, prostate, liver, kidney, breast, abdominal quantitative imaging, cardiac, and musculoskeletal applications.
Collapse
Affiliation(s)
- Sonia Gaur
- Department of Radiology, Michigan Medicine, Ann Arbor, MI
| | - Ananya Panda
- All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
| | | | - Jesse Hamilton
- Department of Radiology, Michigan Medicine, Ann Arbor, MI
| | - Yun Jiang
- Department of Radiology, Michigan Medicine, Ann Arbor, MI
| | - Vikas Gulani
- Department of Radiology, Michigan Medicine, Ann Arbor, MI
| |
Collapse
|
4
|
de Oliveira Correia ET, Qiao PL, Griswold MA, Chen Y, Bittencourt LK. Magnetic resonance fingerprinting based comprehensive quantification of T1 and T2 values of the background prostatic peripheral zone: Correlation with clinical and demographic features. Eur J Radiol 2023; 164:110883. [PMID: 37209463 DOI: 10.1016/j.ejrad.2023.110883] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2023] [Revised: 05/01/2023] [Accepted: 05/10/2023] [Indexed: 05/22/2023]
Abstract
PURPOSE To quantify and assess the distribution of MR fingerprinting (MRF)-derived T1 and T2 values of the whole prostatic peripheral zone (PZ), and perform subgroup analyses according to clinical and demographic features. METHOD One hundred and twenty-four patients with prostate MR exams and MRF-based T1 and T2 maps of the prostatic apex, mid gland, and base were identified from our database and included. Regions of interest encompassing the right and left lobes of the PZ were drawn for each axial slice on the T2 map and copied to the T1 map. Clinical data were obtained from medical records. Kruskal-Wallis test was used for assessing differences between subgroups and the Spearman coefficient was used for assessing any correlations. RESULTS Mean T1 and T2 values were 1941 and 88 ms, respectively, for the whole-gland, 1884 and 83 ms for the apex, 1974 and 92 ms for the mid-gland, 1966 and 88 ms for the base. T1 values were weakly negatively correlated with PSA values, while T1 and T2 values were weakly positively correlated with prostate weight and moderately positively correlated with PZ width. Finally, patients with PI-RADS 1 scores had higher T1 and T2 values of the whole PZ, compared with those with scores 2-5. CONCLUSION Mean T1 and T2 values of the background PZ of the whole gland were 1941 ± 313 and 88 ± 39 ms, respectively. Among clinical and demographic factors, there was a significant positive correlation between T1 and T2 values and PZ width.
Collapse
Affiliation(s)
| | - Peter L Qiao
- Case Western Reserve University, 10900 Euclid Ave, Cleveland, OH 44106, USA.
| | - Mark A Griswold
- University Hospitals Cleveland Medical Center, 11100 Euclid Ave, Cleveland, OH 44106, USA; Case Western Reserve University, 10900 Euclid Ave, Cleveland, OH 44106, USA.
| | - Yong Chen
- Case Western Reserve University, 10900 Euclid Ave, Cleveland, OH 44106, USA.
| | - Leonardo Kayat Bittencourt
- University Hospitals Cleveland Medical Center, 11100 Euclid Ave, Cleveland, OH 44106, USA; Case Western Reserve University, 10900 Euclid Ave, Cleveland, OH 44106, USA.
| |
Collapse
|
5
|
Lo W, Bittencourt LK, Panda A, Jiang Y, Tokuda J, Seethamraju R, Tempany‐Afdhal C, Obmann V, Wright K, Griswold M, Seiberlich N, Gulani V. Multicenter Repeatability and Reproducibility of MR Fingerprinting in Phantoms and in Prostatic Tissue. Magn Reson Med 2022; 88:1818-1827. [PMID: 35713379 PMCID: PMC9469467 DOI: 10.1002/mrm.29264] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2021] [Revised: 02/15/2022] [Accepted: 03/22/2022] [Indexed: 11/12/2022]
Abstract
PURPOSE To evaluate multicenter repeatability and reproducibility of T1 and T2 maps generated using MR fingerprinting (MRF) in the International Society for Magnetic Resonance in Medicine/National Institute of Standards and Technology MRI system phantom and in prostatic tissues. METHODS MRF experiments were performed on 5 different 3 Tesla MRI scanners at 3 different institutions: University Hospitals Cleveland Medical Center (Cleveland, OH), Brigham and Women's Hospital (Boston, MA) in the United States, and Diagnosticos da America (Rio de Janeiro, RJ) in Brazil. Raw MRF data were reconstructed using a Gadgetron-based MRF online reconstruction pipeline to yield quantitative T1 and T2 maps. The repeatability of T1 and T2 values over 6 measurements in the International Society for Magnetic Resonance in Medicine/National Institute of Standards and Technology MRI system phantom was assessed to demonstrate intrascanner variation. The reproducibility between the 4 clinical scanners was assessed to demonstrate interscanner variation. The same-day test-retest normal prostate mean T1 and T2 values from peripheral zone and transitional zone were also compared using the intraclass correlation coefficient and Bland-Altman analysis. RESULTS The intrascanner variation of values measured using MRF was less than 2% for T1 and 4.7% for T2 for relaxation values, within the range of 307.7 to 2360 ms for T1 and 19.1 to 248.5 ms for T2 . Interscanner measurements showed that the T1 variation was less than 4.9%, and T2 variation was less than 8.1% between multicenter scanners. Both T1 and T2 values in in vivo prostatic tissue demonstrated high test-retest reliability (intraclass correlation coefficient > 0.92) and strong linear correlation (R2 > 0.840). CONCLUSION Prostate MRF measurements of T1 and T2 are repeatable and reproducible between MRI scanners at different centers on different continents for the above measurement ranges.
Collapse
Affiliation(s)
- Wei‐Ching Lo
- Department of Biomedical EngineeringCase Western Reserve UniversityClevelandOhio
- Siemens Medical Solutions IncBostonMassachusetts
| | - Leonardo Kayat Bittencourt
- Department of RadiologyUniversity Hospital and Case Western Reserve UniversityClevelandOhio
- DASA companyRio de JaneiroRJBrazil
| | - Ananya Panda
- Department of RadiologyMayo ClinicRochesterMinnesota
| | - Yun Jiang
- Department of RadiologyUniversity of MichiganAnn ArborMichigan
| | - Junichi Tokuda
- Department of Radiology, Harvard Medical SchoolHarvard UniversityBostonMassachusetts
- Department of RadiologyBrigham and Women's HospitalBostonMassachusetts
| | | | - Clare Tempany‐Afdhal
- Department of Radiology, Harvard Medical SchoolHarvard UniversityBostonMassachusetts
- Department of RadiologyBrigham and Women's HospitalBostonMassachusetts
| | - Verena Obmann
- Department of Diagnostic, Interventional and Pediatric Radiology, Inselspital BernUniversity of BernBerneSwitzerland
| | | | - Mark Griswold
- Department of Biomedical EngineeringCase Western Reserve UniversityClevelandOhio
- Department of RadiologyUniversity Hospital and Case Western Reserve UniversityClevelandOhio
| | | | - Vikas Gulani
- Department of RadiologyUniversity of MichiganAnn ArborMichigan
| |
Collapse
|
6
|
Lo WC, Panda A, Jiang Y, Ahad J, Gulani V, Seiberlich N. MR fingerprinting of the prostate. MAGMA (NEW YORK, N.Y.) 2022; 35:557-571. [PMID: 35419668 PMCID: PMC10288492 DOI: 10.1007/s10334-022-01012-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/16/2021] [Revised: 03/21/2022] [Accepted: 03/24/2022] [Indexed: 06/03/2023]
Abstract
Multiparametric magnetic resonance imaging (mpMRI) has been adopted as the key tool for detection, localization, characterization, and risk stratification of patients suspected to have prostate cancer. Despite advantages over systematic biopsy, the interpretation of prostate mpMRI has limitations including a steep learning curve, leading to considerable interobserver variation. There is growing interest in clinical translation of quantitative imaging techniques for more objective lesion assessment. However, traditional mapping techniques are slow, precluding their use in the clinic. Magnetic resonance fingerprinting (MRF) is an efficient approach for quantitative maps of multiple tissue properties simultaneously. The T1 and T2 values obtained with MRF have been validated with phantom studies as well as in normal volunteers and patients. Studies have shown that MRF-derived T1 and T2 along with ADC values are all significant independent predictors in the differentiation between normal prostate tissue and prostate cancer, and hold promise in differentiating low and intermediate/high-grade cancers. This review seeks to introduce the basics of the prostate MRF technique, discuss the potential applications of prostate MRF for the characterization of prostate cancer, and describes ongoing areas of research.
Collapse
Affiliation(s)
- Wei-Ching Lo
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA
- Siemens Medical Solutions USA, Boston, Massachusetts, USA
| | - Ananya Panda
- Department of Radiology, Mayo Clinic, 200 1st Street SW, Rochester, MN, 55905, USA
| | - Yun Jiang
- Department of Radiology, University of Michigan, University of Michigan Health System, 1500 E. Medical Center Drive, Ann Arbor, MI, 48109-5030, USA
| | - James Ahad
- Case Western Reserve University, Cleveland, OH, USA
| | - Vikas Gulani
- Department of Radiology, University of Michigan, University of Michigan Health System, 1500 E. Medical Center Drive, Ann Arbor, MI, 48109-5030, USA
| | - Nicole Seiberlich
- Department of Radiology, University of Michigan, University of Michigan Health System, 1500 E. Medical Center Drive, Ann Arbor, MI, 48109-5030, USA.
- Case Western Reserve University, Cleveland, OH, USA.
| |
Collapse
|
7
|
Ding H, Velasco C, Ye H, Lindner T, Grech-Sollars M, O’Callaghan J, Hiley C, Chouhan MD, Niendorf T, Koh DM, Prieto C, Adeleke S. Current Applications and Future Development of Magnetic Resonance Fingerprinting in Diagnosis, Characterization, and Response Monitoring in Cancer. Cancers (Basel) 2021; 13:4742. [PMID: 34638229 PMCID: PMC8507535 DOI: 10.3390/cancers13194742] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2021] [Revised: 09/08/2021] [Accepted: 09/16/2021] [Indexed: 11/25/2022] Open
Abstract
Magnetic resonance imaging (MRI) has enabled non-invasive cancer diagnosis, monitoring, and management in common clinical settings. However, inadequate quantitative analyses in MRI continue to limit its full potential and these often have an impact on clinicians' judgments. Magnetic resonance fingerprinting (MRF) has recently been introduced to acquire multiple quantitative parameters simultaneously in a reasonable timeframe. Initial retrospective studies have demonstrated the feasibility of using MRF for various cancer characterizations. Further trials with larger cohorts are still needed to explore the repeatability and reproducibility of the data acquired by MRF. At the moment, technical difficulties such as undesirable processing time or lack of motion robustness are limiting further implementations of MRF in clinical oncology. This review summarises the latest findings and technology developments for the use of MRF in cancer management and suggests possible future implications of MRF in characterizing tumour heterogeneity and response assessment.
Collapse
Affiliation(s)
- Hao Ding
- Imperial College School of Medicine, Faculty of Medicine, Imperial College London, London SW7 2AZ, UK;
| | - Carlos Velasco
- School of Biomedical Engineering and Imaging Sciences, St Thomas’ Hospital, King’s College London, London SE1 7EH, UK; (C.V.); (C.P.)
| | - Huihui Ye
- State Key Laboratory of Modern Optical instrumentation, Zhejiang University, Hangzhou 310027, China;
| | - Thomas Lindner
- Department of Diagnostic and Interventional Neuroradiology, University Hospital Hamburg Eppendorf, 20246 Hamburg, Germany;
| | - Matthew Grech-Sollars
- Department of Medical Physics, Royal Surrey NHS Foundation Trust, Surrey GU2 7XX, UK;
- Department of Surgery & Cancer, Imperial College London, London SW7 2AZ, UK
| | - James O’Callaghan
- UCL Centre for Medical Imaging, Division of Medicine, University College London, London W1W 7TS, UK; (J.O.); (M.D.C.)
| | - Crispin Hiley
- Cancer Research UK, Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6DD, UK;
- Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK
| | - Manil D. Chouhan
- UCL Centre for Medical Imaging, Division of Medicine, University College London, London W1W 7TS, UK; (J.O.); (M.D.C.)
| | - Thoralf Niendorf
- Berlin Ultrahigh Field Facility (B.U.F.F.), Max Delbrueck, Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany;
| | - Dow-Mu Koh
- Division of Radiotherapy and Imaging, Institute of Cancer Research, London SM2 5NG, UK;
- Department of Radiology, Royal Marsden Hospital, London SW3 6JJ, UK
| | - Claudia Prieto
- School of Biomedical Engineering and Imaging Sciences, St Thomas’ Hospital, King’s College London, London SE1 7EH, UK; (C.V.); (C.P.)
| | - Sola Adeleke
- High Dimensional Neurology Group, Queen’s Square Institute of Neurology, University College London, London WC1N 3BG, UK
- Department of Oncology, Guy’s & St Thomas’ Hospital, London SE1 9RT, UK
- School of Cancer & Pharmaceutical Sciences, King’s College London, London WC2R 2LS, UK
| |
Collapse
|